• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Achillion Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010 Product Image

Achillion Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010

  • ID: 1446121
  • November 2010
  • 48 pages
  • GlobalData

Achillion Pharmaceuticals, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Achillion Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Achillion Pharmaceuticals, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Achillion Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, READ MORE >



List of Tables
List of Figures
Achillion Pharmaceuticals, Inc. Snapshot
Achillion Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Achillion Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Achillion Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Achillion Pharmaceuticals, Inc. – Pipeline Products Glance
Achillion Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Achillion Pharmaceuticals, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Achillion Pharmaceuticals, Inc. – Drug Profiles
ACH-1625
Product Description
Mechanism of Action
R&D Progress
Elvucitabine
Product Description
Mechanism of Action
R&D Progress
ACH-1095
Product Description
Mechanism of Action
R&D Progress
ACH-2684
Product Description
Mechanism of Action
R&D Progress
ACH-2928
Product Description
Mechanism of Action
R&D Progress
ACH-702
Product Description
Mechanism of Action
R&D Progress
HCV Inhibitor Program
Product Description
Mechanism of Action
R&D Progress
Achillion Pharmaceuticals, Inc. – Pipeline Analysis
Achillion Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Achillion Pharmaceuticals, Inc. Pipeline Products By Target
Achillion Pharmaceuticals, Inc. – Pipeline Products by Molecule Type
Achillion Pharmaceuticals, Inc. - Dormant Projects
Achillion Pharmaceuticals, Inc. – Company Statement
Achillion Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Sep 30, 2010: Achillion Doses First Patient In Phase II Trial Of ACH-1625 For Treatment Of Hepatitis C
Jul 22, 2010: Achillion Announces Nomination Of NS5A Inhibitor As Lead Clinical Candidate For Treatment Of HCV
May 11, 2010: Achillion Announces Positive Once-Daily Dosing Results With ACH-1625 To Treat Hepatitis C
Apr 15, 2010: Achillion Presents Data From Phase I Clinical Trial Of ACH-1625 In Hepatitis C
Mar 25, 2010: Achillion Receives Patent For NS4A
Mar 25, 2010: Achillion Receives Patent For NS4A
Mar 25, 2010: Achillion Receives Patent For NS4A
Mar 25, 2010: Achillion Receives Patent For NS4A
Mar 25, 2010: Achillion Receives Patent For NS4A
Mar 25, 2010: Achillion Receives Patent For NS4A
Financial Deals Landscape
Achillion Pharmaceuticals, Inc., Deals Volume Summary, 2004 to YTD 2010
Achillion Pharmaceuticals, Inc., Deals Summary By Region, 2004 to YTD 2010
Achillion Pharmaceuticals, Inc., Deals Summary, 2004 to YTD 2010
Achillion Pharmaceuticals, Inc. Detailed Deal Summary
Equity Offering
Achillion Pharmaceuticals Completes Public Offering Of $25 Million
Achillion Pharmaceuticals Announces Private Placement Of $15 Million
Achillion Pharmaceuticals Completes Initial Public Offering Of $59.5 Million
Licensing Agreements
Achillion Pharmaceuticals Enters Into Licensing Agreement With GCA Therapeutics
Achillion Pharmaceuticals Enters Into Licening Agreement With FOB Synthesis
Achillion Pharmaceuticals Enters Into Licensing Agreement with Gilead Sciences
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS